WOBURN, Mass.--(BUSINESS WIRE)--We are pleased to announce that Aphios® Pharma LLC will host a live webinar followed by Q&A on the business of cannabis as a pharmaceutical medicine.
This webinar will cover the business of cannabis as a pharmaceutical medicine, touching on the business of cannabis in recreational and medical use. We will show you our competitors and competitive advantages in the pharmaceutical marketplace. We will present estimates of the total and accessible marketplaces for our first-generation products targeting generalized social anxiety disorder (GSAD), chemotherapy induced peripheral neuropathic pain (CIPNP), opioid use disorder (OUD), and pain and spasticity associated with Multiple Sclerosis (PSAMS). We will then layout our product development plans and commercialization strategies for each identified segment of our market. The webinar will close with investment, financing and exit strategies.
Join Aphios® Pharma founder and CEO Dr. Trevor P. Castor, along with guests Dr. Val R. Livada, Business Advisor and Controller Catherine Prillo, on July 14, 2022, from 12 pm to 12:45 pm EST, for a discussion on the financial aspects of cannabis as a medicine and the drug-delivery nanotechnologies that make cannabis more effective.
To learn more and register for the event, visit:
Aphios® Pharma: Ending Soon Event Tickets, Thu, Jul 14, 2022 at 12:00 PM | Eventbrite
About Aphios® Pharma LLC:
Aphios® Pharma, a green biotech company, is dedicated to the delivery, development and commercialization of cannabis-based drugs for several debilitating disorders. We are developing FDA-approved, cannabis-based drugs for treating highly unmet central and peripheral nervous system disorders such as anxiety, addiction, pain and multiple sclerosis that are only acutely addressed by medical marijuana dispensaries. Aphios® Pharma is utilizing patented and proprietary SuperFluids™ manufacturing technologies for producing pharmaceutical-grade cannabinoids, and patented and proprietary SuperFluids™ drug delivery nanotechnologies to improve the oral and topical bioavailability of disease-specific cannabinoids and control their release for the treatment of chronic diseases. We are thus converting natural drugs that are anecdotally used to treat acute conditions into well-defined and characterized drugs for chronic conditions.
